Siemens recognized for life sciences R&D technology

AI-generated summary

Siemens has been named a Leader in IDC MarketScape’s 2026 assessment of worldwide life sciences R&D laboratory technology solutions and consulting services. The assessment evaluates providers’ current capabilities and strategies for the next three to five years. The recognition comes as life sciences companies seek to modernize fragmented laboratory systems while addressing increasingly complex regulatory requirements. IDC identifies Siemens’ coverage of the pharmaceutical value chain as a key differentiator, extending from R&D through pilot operations, scale-up and commercial manufacturing, as well as buildings and electrification. Other strengths cited include its digital twin and AI-enabled portfolio, open and vendor-agnostic Smart Lab Ecosystem, and Enterprise Recipe Management approach based on the ISA-88 standard. Siemens describes its “Lab of the Future” as a connected, AI-enabled scientific environment in which data, models and workflows flow across discovery, development, scale-up and manufacturing. A concrete modeling example involves AstraZeneca’s use of Siemens’ gPROMS-formulated products process modeling technology to investigate tablet manufacturing. AstraZeneca developed a flowsheet model covering dry granulation and tableting, then ran more than 3,000 virtual experiments to assess how material properties and process parameters affect product quality attributes. According to the report, this approach produced significant savings in time, resources and materials compared with physical experimentation, although the article does not quantify those savings. The assessment also highlights Siemens’ Smart Lab Ecosystem, a modular infrastructure kit designed to support adaptable research spaces. Its vendor-agnostic architecture allows laboratory room segments, devices and sensors to be combined in flexible, plug-and-play configurations. The article cites independent testing with Switzerland’s University of Applied Sciences Luzern under Project PEARL. Siemens reports a 31% improvement in local air change rate, 29% faster particle removal and 45% better ventilation efficiency, alongside up to 60% faster laboratory design and construction and up to an 80% reduction in changeover time between laboratory configurations. Siemens’ 2025 acquisition of Dotmatics is presented as another step in extending its digital thread upstream into drug discovery and connecting scientific research with industrial execution. Dotmatics Luma, described as an AI-native scientific intelligence platform, connects laboratory instruments, scientific applications and enterprise systems within a unified data environment. The intended benefit is faster, better-informed decision-making throughout the product lifecycle. Luma is part of Siemens Xcelerator, the company’s open digital business platform. Overall, the article positions Siemens’ combination of scientific data integration, process modeling, flexible laboratory infrastructure and manufacturing capabilities as a foundation for a continuous digital thread across pharmaceutical product and production lifecycles. The emphasis is on linking research with downstream development and industrial operations rather than treating laboratory modernization as an isolated activity. The article provides a customer modeling example and Siemens-reported laboratory performance figures, but does not discuss implementation limitations, risks or detailed deployment requirements.